

are derived from tumor antigens which are expressed by said patient and bind to an MHC-I or MHC-II molecule.

68. The process of claim 55, wherein said process further comprises:

(a) incubating fibroblasts with one or more of a third set of peptides in the presence of an organic polycation, for such a time and in such a quantity that said third set of peptides are bound to said fibroblasts in such a way that said third set of peptides are recognized as foreign by said patient's immune system in context with said fibroblasts and trigger a cellular immune response; wherein said third set of peptides are derived from tumor antigens which are expressed by said patient; and

(b) mixing said fibroblasts with said tumor cells.--

Remarks

No new matter has been added. Claims 1-35 have been cancelled without prejudice or disclaimer of their subject matter and new claims 36-68 have been added. Upon entry of this Amendment, claims 36-68 are pending in the application, with claims 36, 55, 66, and 67 as the independent claims. The specification has been amended to direct the entry of this sequence listing between the specification and claims of the above identified application, to provide the SEQ ID NO's next to the specific sequence, and to correct a typographical error. Support for the amendments to the specification and the claims can be found throughout the specification, for example, at pages 19 and 23 and in the claims as originally filed.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

Summary

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Raz E. Fleshner
Attorney for Applicants
Registration No. 34,331

Date: May 26, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600